Novo Nordisk is introducing a higher dose of Wegovy

It was recently made clear that Tirzepatide (Zepbound, Mounjaro) is more effective than Semaglutide (Ozempic, Wegovy, Rybelsus):

Semaglutide vs Tirzepatide (Clinical trial)

Finally, a research clinical trial that directly explores the difference between Semaglutide and Tirzepatide for Obesity.

GLP1 GuideGLP1.Guide Staff

That said, Novo Nordisk isn't standing still - they're introducing a higher dosage of Wegovy that was deemed tolerable in trials for people to use and achieve higher weight loss.

Currently the dosages that are listed in the prescription information for Wegovy are:

• 0.25 mg/0.5 mL
• 0.5 mg/0.5 mL
• 1 mg/0.5 mL
• 1.7 mg/0.75 mL
• 2.4 mg/0.75 mL

Novo Nordisk is trying to introduce a 7.2mg dosage, which is quite a bit higher than their existing highest dose.

Is Novo Nordisk Increasing Dosage to Defend Wegovy’s Edge in Obesity?

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.

Zacks Investment ResearchAhan Chakraborty

While this currently applies to Europe (Novo has filed with the European Medicines Agency), Novo has expressed interest in pursuing this for other geographies as well, so it seems to be a wide-ranging strategy.

We'll get into the additional side effects, dosage schedule, and the study that Novo didn't cite below.

The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack: